2021
Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants
Thompson SL, Gianessi CA, O'Malley SS, Cavallo DA, Shi JM, Tetrault JM, DeMartini KS, Gueorguieva R, Pittman B, Krystal JH, Taylor JR, Krishnan-Sarin S. Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants. Frontiers In Psychiatry 2021, 12: 709559. PMID: 34531767, PMCID: PMC8438169, DOI: 10.3389/fpsyt.2021.709559.Peer-Reviewed Original ResearchNMDA receptorsSrc/FynAlcohol consumptionEffect of saracatinibVehicle 2 hChronic alcohol useDays of treatmentDSM-IV criteriaMore effective treatmentsNumber of drinksGlutamatergic systemAdditional drinkAlcohol drinkingAdditional dosesEthanol exposureEffective treatmentNR2B subunitAlcohol abuseHuman studiesPriming drinkAlcohol cravingSaracatinibDrinking paradigmNovel pharmacotherapeuticsHuman participants
2019
Randomized Pilot Trial of Web-Based Cognitive-Behavioral Therapy Adapted for use in Office-Based Buprenorphine Maintenance
Shi JM, Henry SP, Dwy SL, Orazietti SA, Carroll KM. Randomized Pilot Trial of Web-Based Cognitive-Behavioral Therapy Adapted for use in Office-Based Buprenorphine Maintenance. Substance Use & Addiction Journal 2019, 40: 132-135. PMID: 30714880, PMCID: PMC6874094, DOI: 10.1080/08897077.2019.1569192.Peer-Reviewed Original ResearchConceptsOffice-based buprenorphineOpioid use disorderBuprenorphine treatmentWeb-based interventionBuprenorphine maintenancePilot trialUse disordersBehavioral careCurrent opioid use disorderOffice-based buprenorphine treatmentUrine toxicology screenSpecific patient populationsDays of treatmentDSM-5 criteriaCognitive behavioral therapyInitial pilot testingToxicology screenPatient populationTwelve-weekEffective treatmentBuprenorphineDrug useSmall sample sizeTrialsPromising findings